B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

TGFBR1

MOLECULAR TARGET

transforming growth factor beta receptor 1

UniProt: P36897NCBI Gene: 704625 compounds

TGFBR1 (transforming growth factor beta receptor 1) is targeted by 25 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting TGFBR1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1sb 2035804.92136
2tozasertib4.3375
3nintedanib3.6136
4canertinib3.5333
5tae 6843.4330
6saracatinib3.3327
7sb 4315423.3327
8dabrafenib3.3026
9dorsomorphin3.1422
10at 92833.0921
11lestaurtinib3.0420
12danusertib2.9418
13galunisertib2.9418
14momelotinib2.8917
15r 4062.8316
16k 252a2.8316
17cediranib2.8316
18mk 51082.4811
19vactosertib2.4010
20gsk 10709162.208
21cyc 1162.087
22osi 0272.087
23osi 6321.795
24Crizotinib0.691
25Dasatinib0.691

About TGFBR1 as a Drug Target

TGFBR1 (transforming growth factor beta receptor 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 25 compounds with documented TGFBR1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

TGFBR1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.